An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs LY900021 (Primary) ; Mirikizumab (Primary)
- Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 15 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.
- 01 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.